Small Business

Novartis gains on plans of Alcon buy

Novartis has ended the day at Rs 572, stronger by Rs 14 or 2.6%, on the BSE. - Novartis to get leg-up in India with Alcon buy - Novartis to buy majority stake in Alcon for $28.1 bn - Sugar stocks jump as prices touch record high - Tata Motors hits new 52-wk high on Dec sales nos - Cox & Kings pares gains, ends flat - NTPC hits 52-wk high on disinvestment plans The stock had touched a high of Rs 600 and a low of Rs 565 during the course of the day. A total of 12,493 shares were traded on the counter as against the two-week average of 3,783 shares. _____________________________________________________ (Updated at 0955am) Novartis India has gained 4% in morning trades on plans to buy a majority stake in Alcon. The stock opened at the day"s high of Rs 600 - which is also the 52-week high. It is now up 4% at Rs 580. Around 2,113 shares have been traded on the BSE so far. Drug major, Novartis plans to buy a majority stake in the world"s largest eye-care company, Alcon. Novartis today agreed to pay $28.1 billion (nearly Rs 1.3 lakh crore) to raise its stake in Alcon — a $6.3-billion (nearly Rs 30,000-crore) turnover, 65-year-old company — to 77%. Nestle had bought Alcon in 1977 for $280 million. It sold a 25 per cent stake in the company to Novartis in 2008 for $10.4 billion.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

News of the day
SBI Life: Catch 'em young
Life insurers have begun to spend big money on brand promotion. The market, after all, is crowded. At last count, there were 22 companies in the fray for a market estimated at Rs 55,355 crore. SBI Life, the 74:26 venture of State Bank of India and BNP Paribas Assurance, has been not as aggressive as its rivals so far as brand promotion is concerned. Where others rolled out campaign after campaign, SBI Life stuck to its old campaigns. It is only now, after a two-year hiatus, that it has come out with a brand new advertising campaign.
Popular Articles

Govt to announce stimulus for select exporters soon
Decides to provide extra helping hand after a sectoral review

AIG of drugmakers, Pfizer is too big to be guilty
Pfizer Inc sales folks had one tough customer in psychiatrist Stefan Kruszewski. He didn’t buy their pitch to prescribe the anti-psychotic drug Geodon to children, a use that hadn’t been approved by federal regulators. Nor did he go for the so-called off-label uses, such as treating dementia in the elderly, they suggested.